Apollomics Net Invested Capital from 2010 to 2025

APLM Stock   7.51  0.65  7.97%   
Apollomics Net Invested Capital yearly trend continues to be very stable with very little volatility. Net Invested Capital is likely to grow to about 54.9 M this year. Net Invested Capital is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. View All Fundamentals
 
Net Invested Capital  
First Reported
2010-12-31
Previous Quarter
52.3 M
Current Value
54.9 M
Quarterly Volatility
116.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Apollomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apollomics' main balance sheet or income statement drivers, such as Tax Provision of 12.1 K, Net Interest Income of 728.1 K or Interest Income of 544.8 K, as well as many indicators such as Price To Sales Ratio of 9.6 K, Dividend Yield of 0.0 or PTB Ratio of 165. Apollomics financial statements analysis is a perfect complement when working with Apollomics Valuation or Volatility modules.
  
Check out the analysis of Apollomics Correlation against competitors.

Latest Apollomics' Net Invested Capital Growth Pattern

Below is the plot of the Net Invested Capital of Apollomics Class A over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. Apollomics' Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apollomics' overall financial position and show how it may be relating to other accounts over time.
Net Invested Capital10 Years Trend
Pretty Stable
   Net Invested Capital   
       Timeline  

Apollomics Net Invested Capital Regression Statistics

Arithmetic Mean(119,723,717)
Coefficient Of Variation(97.56)
Mean Deviation63,979,585
Median(127,933,000)
Standard Deviation116,799,893
Sample Variance13642.2T
Range503M
R-Value0.21
Mean Square Error13967.1T
R-Squared0.04
Significance0.43
Slope5,171,651
Total Sum of Squares204633.2T

Apollomics Net Invested Capital History

202554.9 M
202452.3 M
202345.5 M
2022-448.1 M
2021-212.9 M

About Apollomics Financial Statements

Apollomics investors utilize fundamental indicators, such as Net Invested Capital, to predict how Apollomics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Invested Capital52.3 M54.9 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Apollomics Class A is a strong investment it is important to analyze Apollomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apollomics' future performance. For an informed investment choice regarding Apollomics Stock, refer to the following important reports:
Check out the analysis of Apollomics Correlation against competitors.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.15)
Revenue Per Share
0.023
Quarterly Revenue Growth
2.623
Return On Assets
(0.63)
Return On Equity
(1.49)
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apollomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.